Table 1.

Demographics

Groups (numbers)	FP (n=23)	Placebo (n=11)	Normal controls
Age (years)	61 (46–69)	61 (52–69)	44 (20–68)
Female/male	9/14	4/7	7/8
Current smoker/ex-smoker	13/10	4/7	N/A
Pack-year smoking history	44 (18–150)	51 (22–148)	N/A
GOLD stage I/II†	12/11	5/6	N/A
FEV1/FVC ratio (post-BD)*	59 (41–68)	57 (38–68)	82 (71–88)

Notes:

^†Diagnosis of mild-to-moderate COPD was made according to GOLD guidelines;

^*post-BD values after 400 μg of albuterol. There was no statistically significant difference between the groups at baseline. Data are expressed as medians and ranges.

Abbreviations: BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FP, fluticasone propionate; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; N/A, not available